Press Releases

Press Releases

Date Title Files

Feb 04, 2021

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 04, 2021

Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Feb 01, 2021

Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government

Feb 01, 2021

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

Feb 01, 2021

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Jan 25, 2021

Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Jan 20, 2021

Dynavax Appoints Kelly MacDonald as Chief Financial Officer

Jan 07, 2021

Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Jan 06, 2021

Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference